School of Medicine
Showing 101-108 of 108 Results
Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Current Research and Scholarly Interests 1) Amyloidosis -- Optimizing diagnosis/therapy and discovering new treatments
2) CardioOncology -- Understanding, treating, and preventing cancer therapy-induced cardiotoxicity
3) Sarcoidosis -- Exploring novel diagnostic modalities and determining optimal treatment, with a focus on cardiac sarcoidosis
Joseph C. Wu
Director, Stanford Cardiovascular Institute, Simon H. Stertzer, MD, Professor and Professor of Radiology
Current Research and Scholarly Interests Drug discovery, drug screening, and disease modeling using biobank of cardiac iPSC lines.
Sean M. Wu
Associate Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Pediatrics
Current Research and Scholarly Interests My lab seeks to identify mechanisms regulating cardiac lineage commitment during embryonic development and the biology of cardiac progenitor cells in development and disease. We believe that by understanding the transcriptional and epigenetic basis of cardiomyocyte growth and differentiation, we can identify the most effective ways to repair diseased adult hearts. We employ mouse and human embryonic and induced pluripotent stem cells as well as rodents as our in vivo models for investigation.
Phillip C. Yang, MD
Associate Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Current Research and Scholarly Interests Dr. Yang is a physician-scientist whose research interest focuses on clinical translation of the fundamental molecular and cellular processes of myocardial restoration. His research employs novel in vivo multi-modality molecular and cellular imaging technology to translate the basic innovation in cardiovascular pluripotent stem cell biologics. Dr. Yang is currently a PI on the NIH/NHLBI funded CCTRN UM1 grant, which is designed to conduct multi-center clinical trial on novel biological therapy.
Alan Yeung, MD
The Li Ka Shing Professor in Cardiology
Current Research and Scholarly Interests Coronary artery disease is the leading cause of death in men and women in the United States. Our group is interested in studying both the early and late phases of atherosclerosis so that we can better develop prevention and treatment strategies.
Paul Yock, MD
The Martha Meier Weiland Professor in the School of Medicine, Professor of Bioengineering and, by courtesy, of Mechanical Engineering
Current Research and Scholarly Interests Health technology innovation using the Biodesign process: a systematic approach to the design of biomedical technologies based on detailed clinical and economic needs characterization. New approaches for interdisciplinary training of health technology innovators, including processes for identifying value opportunities in creating new technology-based approaches to health care.
Celina Yong, MD, MBA, MSc
Assistant Professor of Medicine (Cardiovascular Medicine) at the Stanford University Medical Center
Bio Celina Yong, MD, MBA, MSc is Director of Interventional Cardiology at the Palo Alto VA Medical Center and an Assistant Professor in the Division of Cardiovascular Medicine at Stanford. Dr. Yong completed her medical training at Stanford School of Medicine and her internal medicine residency at the University of California, San Francisco. She completed her cardiology and interventional cardiology fellowships at Stanford, including a year as Chief Fellow. As a Marshall Scholar, she completed a Masters in Health Policy, Planning and Financing from the London School of Economics and an MBA from Oxford.
Dr. Yong?s current research focuses on understanding and innovating scalable technologies to reduce inequities in cardiovascular care for patients. Specifically, she is interested in understanding and resolving racial, gender, geographic, and socioeconomic disparities in access to high quality minimally invasive treatments, as well as gender imbalances in the medical profession itself. She is also actively involved in clinical trials of novel devices for percutaneous coronary and structural intervention, and manages the structural heart program based at the Palo Alto VA Hospital.